John Westwater

John Westwater is the Chief Financial Officer at Elastagen Pty Ltd. since 2015. John has over thirteen years experience in the life science financial industry, eight years as a venture capital investor and remainder as an investment banking professional. Prior to joining Elastagen John was at Phase4 Ventures (formerly Nomura Phase4 Ventures), a global life science VC firm based in London. During this period he was actively involved with several investments both in the US and Europe: including Nabriva Therapeutics, Paratek Pharmaceuticals, Zosano Pharma and Acadia Pharmaceuticals. John has also spent over four years with Morgan Stanley in their healthcare corporate finance and Mergers & Acquisitions teams. During this period he had a key role in the development and execution of Elan Corp’s recovery plan between 2002 and 2003, which involved over $1Bn in disposal proceeds and the restructuring of its balance sheet, as well as several biotech initial public offerings. John holds a Ph.D. and B.Sc. degree (Hons) in Biochemistry from Heriot-Watt University in Scotland and was awarded the Watt Club Medal.